Fig. 4
From: Recent advances of CREKA peptide-based nanoplatforms in biomedical applications
Biodistribution and targeting performance of TG NPs. a In vivo fluorescence images in jugular venous thrombosis model rats treated with TG NPs or non-targeted NPs. b In vivo thrombosis fluorescence intensity at the corresponding time point. c In vivo fluorescence image of major organ after 6Â h intravenous injection. d Ex vivo fluorescence intensity of thrombosis 6Â h after intravenous administration of TG NPs or non-targeted NPs. e Fluorescence images of thrombus sections after treatment with TG NPs or non-targeted NPs [64]